NASDAQ$CRBU
Caribou Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported business highlights and financial results for the second quarter of 2021.
Caribou Biosciences reported a net loss of $14.3 million for the second quarter of 2021. The company completed an upsized IPO raising $349.6 million in gross proceeds and dosed the first patient in Phase 1 clinical trial of CB-010.
- Dosed the first patient in Phase 1 clinical trial of CB-010.
- Completed upsized IPO raising $349.6 million in gross proceeds.
- Expanded Caribou’s board of directors with appointment of Nancy Whiting, Pharm.D.
- Published data demonstrating the significantly improved specificity of Caribou’s proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology compared to all-RNA guides.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$0
Revenue by segment
Caribou Biosciences · $1.48M total across 1 segment · Q2 2021
- Licensing & collaboration$1.48M-82.6%100.0%
Forward guidance
Caribou expects initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL in 2022. Caribou expects to file an Investigational New Drug (IND) application for its CB-011 program in 2022. Caribou expects to file an IND application for its CB-012 program in 2023. Caribou expects to announce target selection for its CB-020 program in 2022.
Tailwinds
- Initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL is expected in 2022.
- An Investigational New Drug (IND) application for its CB-011 program is expected to be filed in 2022.
- An IND application for its CB-012 program is expected to be filed in 2023.
- Target selection for its CB-020 program is expected to be announced in 2022.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells engineered using Cas9 chRDNA technology.
Headwinds
- Risks inherent in drug development
- Risks associated with the initiation, cost, timing, progress and results of current and future research and development programs
- Risks associated with preclinical studies
- Risks associated with clinical trials
- Uncertainties in forward-looking statements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro